Mabworks Biotech is focused on developing innovative antibody therapies aimed at treating autoimmune diseases and cancers. The company has established a differentiated pipeline of clinical-stage and preclinical drug candidates, utilizing proprietary antibody discovery and development platforms. Notable candidates include MIL62, a third-generation anti-CD20 antibody that has received breakthrough designation for treating primary membranous nephropathy, and MBS303/MSC303, a CD20/CD3 T-cell engager designed to target B-cell non-Hodgkin lymphoma and immune-mediated glomerulonephritis. Additionally, MBS314 is a GPRC5D/BCMA/CD3 T-cell engager that offers potential treatment options for multiple myeloma patients.

To support its therapeutic development, Mabworks has built several proprietary technology platforms that enhance the efficacy of its antibody candidates. The ADCC-enhanced Antibody Platform improves natural killer (NK) cell function through glycosylation modifications, while the Multi-specific Antibody Platform allows for the rapid construction of antibodies that can bind to multiple targets, promoting synergistic therapeutic effects. Furthermore, the Antibody Discovery and Optimization Platform is designed to identify candidates with high binding affinity and stability, ensuring the development of effective and safe therapeutics. These platforms collectively enable Mabworks to efficiently design, evaluate, and develop optimal drug candidates for clinical use.

China

Mab Works is committed to bringing novel therapeutics to patients and aspires to become a globally integrated biopharmaceutical company. Their mission is to translate innovative science into value for patients and shareholders.

Mabworks Biotech

Company Details